IF benefits questioned
A new study is prompting a broad rethink of intermittent fasting — researchers and commentators say metabolic and weight‑loss advantages may not be universal and that IF’s sustainability is in question compared with calorie‑controlled approaches report analysis.
A Cochrane review published Feb 16, 2026 found (cochrane.org) that intermittent‑fasting regimens produced no clinically meaningful weight‑loss advantage across 22 randomized trials involving 1,995 adults. The review reported the pooled difference between intermittent fasting and conventional diets was just 0.33 percentage points of body weight, and in six trials IF beat no‑intervention by about 3.4% of body weight — below the 5% benchmark often cited for meaningful health benefit. (rutgers.edu) The ChronoFast randomized crossover trial in 31 women compared early (08:00–16:00) versus late (13:00–21:00) eight‑hour time‑restricted eating windows and, in an intended isocaloric design, found no improvement in insulin sensitivity, 24‑hour glucose patterns, lipids or inflammatory markers. (science.org) ChronoFast’s lead investigator Olga Pivovarova‑Ramich (DIfE/Charité) and supporting press releases concluded the apparent benefits in prior TRE studies were likely driven by unintended calorie reduction rather than meal timing itself. (dzd-ev.de) Cochrane and accompanying coverage emphasized study limitations: most trials were small, none lasted longer than one year, adherence was often self‑reported, diabetes outcomes were not assessed, and 19 of 22 trials enrolled predominantly white participants in high‑income countries. (cochrane.org) The literature remains mixed: a 2025 trial at the University of Colorado Anschutz reported higher adherence and greater weight loss for a 4:3 IF regimen in that study, while broader network meta‑analyses and the BMJ review note inconsistent effects across IF modalities and populations. (news.cuanschutz.edu)
